Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13966421 | 1.00 | ADORA3 (0.50) | ADORA3ADORA2BADORA1TSHRCYP3A4 | |
| SCHEMBL17367923 | 0.86 | CCNB2 (0.50) | — | |
| SCHEMBL19443158 | 0.86 | CCNB2 (0.50) | — | |
| SCHEMBL13975624 | 0.85 | PI4KA (0.61) | ADORA3ADORA1 | |
| SCHEMBL21139430 | 0.85 | PI4KA (0.61) | ADORA3ADORA1 | |
| SCHEMBL13966414 | 0.85 | PI4KA (0.61) | ADORA3ADORA1 | |
| SCHEMBL17371116 | 0.85 | PI4KA (0.61) | ADORA3ADORA1 | |
| SCHEMBL21139458 | 0.84 | SLC29A1 (0.54) | ADORA3ADORA1 | |
| SCHEMBL13966415 | 0.84 | CCNB2 (0.52) | ADORA3ADORA1 | |
| SCHEMBL20435006 | 0.81 | PI4KA (0.56) | ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295863-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ACADEMIA SINICA (TW) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295863-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA2B 7/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.